These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 14741394)

  • 1. SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease.
    Wang W; Shi L; Xie Y; Ma C; Li W; Su X; Huang S; Chen R; Zhu Z; Mao Z; Han Y; Li M
    Neurosci Res; 2004 Feb; 48(2):195-202. PubMed ID: 14741394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease.
    Wang Y; Zhang Y; Wei Z; Li H; Zhou H; Zhang Z; Zhang Z
    J Neurol Sci; 2009 Oct; 285(1-2):172-7. PubMed ID: 19604516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo.
    Saporito MS; Thomas BA; Scott RW
    J Neurochem; 2000 Sep; 75(3):1200-8. PubMed ID: 10936203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
    J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutathione S-transferase pi mediates MPTP-induced c-Jun N-terminal kinase activation in the nigrostriatal pathway.
    Castro-Caldas M; Carvalho AN; Rodrigues E; Henderson C; Wolf CR; Gama MJ
    Mol Neurobiol; 2012 Jun; 45(3):466-77. PubMed ID: 22539231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effects of (+/-)-catechin against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mice.
    Ruan H; Yang Y; Zhu X; Wang X; Chen R
    Neurosci Lett; 2009 Jan; 450(2):152-7. PubMed ID: 19070648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of phosphorylated c-Jun expression on COX-2 expression in the substantia nigra of MPTP mouse model of subacute Parkinson disease].
    Wang YS; Zhou JP; Wei ZF; Tian QY; Zhou HX; Zhang YX
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1199-202, 1205. PubMed ID: 17715026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease.
    Xia XG; Harding T; Weller M; Bieneman A; Uney JB; Schulz JB
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10433-8. PubMed ID: 11504916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the c-Jun N terminal kinase pathway in an animal model of Parkinson's disease.
    Willesen MG; Gammeltoft S; Vaudano E
    Ann N Y Acad Sci; 2002 Nov; 973():237-40. PubMed ID: 12485868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway.
    Yu S; Zheng W; Xin N; Chi ZH; Wang NQ; Nie YX; Feng WY; Wang ZY
    Rejuvenation Res; 2010 Feb; 13(1):55-64. PubMed ID: 20230279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.
    Du Y; Ma Z; Lin S; Dodel RC; Gao F; Bales KR; Triarhou LC; Chernet E; Perry KW; Nelson DL; Luecke S; Phebus LA; Bymaster FP; Paul SM
    Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14669-74. PubMed ID: 11724929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.
    Boyd JD; Jang H; Shepherd KR; Faherty C; Slack S; Jiao Y; Smeyne RJ
    Brain Res; 2007 Oct; 1175():107-16. PubMed ID: 17884023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity.
    Wang W; Yang Y; Ying C; Li W; Ruan H; Zhu X; You Y; Han Y; Chen R; Wang Y; Li M
    Neuropharmacology; 2007 Jun; 52(8):1678-84. PubMed ID: 17517424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of the translocation and activation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease.
    Pan J; Xiao Q; Sheng CY; Hong Z; Yang HQ; Wang G; Ding JQ; Chen SD
    Neurochem Int; 2009 Jun; 54(7):418-25. PubMed ID: 19428783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
    Karunakaran S; Diwakar L; Saeed U; Agarwal V; Ramakrishnan S; Iyengar S; Ravindranath V
    FASEB J; 2007 Jul; 21(9):2226-36. PubMed ID: 17369508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JNK inhibition as a potential strategy in treating Parkinson's disease.
    Wang W; Ma C; Mao Z; Li M
    Drug News Perspect; 2004 Dec; 17(10):646-54. PubMed ID: 15696229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective properties of icariin in MPTP-induced mouse model of Parkinson's disease: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
    Chen WF; Wu L; Du ZR; Chen L; Xu AL; Chen XH; Teng JJ; Wong MS
    Phytomedicine; 2017 Feb; 25():93-99. PubMed ID: 28190476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JNK-mediated activation of ATF2 contributes to dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease.
    Huang Q; Du X; He X; Yu Q; Hu K; Breitwieser W; Shen Q; Ma S; Li M
    Exp Neurol; 2016 Mar; 277():296-304. PubMed ID: 26515688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.